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Background: Glucocorticoid (GC) action in inflammation is important but poorly understood.
Results: Merm1 regulates glucocorticoid receptor (GR) recruitment to the genome and mediates subsequent histone modifi-
cation. Proinflammatory cytokine induction of GC resistance is accompanied by Merm1 degradation; restoration of Merm1
expression rescues GC action.
Conclusion:Merm1 is a novel GR co-modulator.
Significance:Merm1 mediates inflammation regulation of GC action.
Glucocorticoids (GC) regulate cell fate and immune function.
We identified the metastasis-promoting methyltransferase,
metastasis-related methyltransferase 1 (WBSCR22/Merm1) as
a novel glucocorticoid receptor (GR) regulator relevant to
humandisease.Merm1binds theGRco-activatorGRIP1butnot
GR. Loss of Merm1 impaired both GR transactivation and tran-
srepressionby reducingGRrecruitment to its binding sites.This
was accompanied by loss of GR-dependent H3K4Me3 at a well
characterizedpromoter. InflammationpromotesGC resistance,
in part through the actions of TNF and IFN. These cytokines
suppressedMerm1protein expressionbydrivingubiquitination
of two conserved lysine residues. Restoration of Merm1 expres-
sion rescued GR transactivation. Cytokine suppression of
Merm1 and of GR function was also seen in human lung
explants. In addition, striking loss of Merm1 protein was
observed in both inflammatory and neoplastic human lung
pathologies. In conclusion, Merm1 is a novel regulator of chro-
matin structure affectingGR recruitment and function, contrib-
uting to loss of GC sensitivity in inflammation, with suppressed
expression in pulmonary disease.
Glucocorticoids (GC)6 exert diverse effects on multiple cell
types and tissues, affecting energy metabolism, cell fate, and
differentiated function. Variation in GC sensitivity is evident in
several disease states, with resistance occurring in chronic
inflammatory diseases including rheumatoid arthritis, asthma,
and chronic obstructive pulmonary disease through mecha-
nisms that remain undefined but are thought to result from
cytokine action (1–4). In addition, human small cell lung can-
cer is characterized by GC resistance, which prevents GC
induction of cell death both in vitro and in vivo (5, 6).
The diverse actions of GC are mediated through the ubiqui-
tously expressed glucocorticoid receptor (GR). GR is a nuclear
hormone receptor that acts as a ligand-inducible transcription
factor interacting with chromatin to regulate gene transcrip-
tion (7–9). Selection of GR binding sites is dependent on cell
type-specific chromatin structure, which regulates accessibility
to target DNA, giving rise to cell type-specific GR cistromes
(10–13).
Regulation of transcription by GR is mediated by co-modu-
lator proteins, some of which regulate post-translational mod-
ification of histone proteins (e.g. p160, CARM1, CBP) and some
that do not (e.g. SWI/SNF) (14, 15). Changes in post-transla-
tional modifications on core histone tails, particularly acetyla-
tion and methylation, critically affect chromatin structure and
gene expression. Much attention has been given to histone
acetylation, a transient mark that renders nucleosomal DNA
more accessible to protein binding (16). However, histone
methylation is also important. In the context of GR-regulated
gene transcription the histone arginine methyltransferase
CARM1 plays a prominent role (17).
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Histone acetylation regulates the charge on the histone tail
and relaxes the association with DNA, thereby “opening” chro-
matin to transcription factor binding. In contrast, histone
methylationhas no effect on charge but likely serves as a protein
recognition surface (18, 19). Histone methylation involves
three groups of protein complexes: “writers,” or histone meth-
yltransferases, “erasers,” or histone demethylases, and “read-
ers,” or proteins recruited to the methylated histones. Three
families of enzymes result in histone methylation. The SET
domain, andDOT1-like proteins bothmethylate lysine, and the
protein arginine N-methyltransferase (PRMT) family methyl-
ate arginine residues (20). Recent evidence points toward coor-
dinated modification of multiple histone residues at a given
locus, an effect regulated by long non-coding RNAs (lncRNA),
such as hotair (20).
We have identified the WBSCR22/metastasis-related meth-
yltransferase 1 (Merm1) gene as an important regulator of GR
binding and function and a mediator of cytokine-induced glu-
cocorticoid resistance. Merm1/wbscr22 is one of 26–28 genes
deleted from7q11.23 inWilliams-Beuren syndrome, a develop-
mental disorder with multisystem manifestations, including
glucose intolerance and diabetes mellitus (21).
Merm1 is highly conserved through evolution from Saccha-
romyces cerevisiae and Caenorhabditis elegans to humans.
RNAi-mediated knockdown of the Merm1 ortholog in
C. elegans is embryonic lethal (22). Based on the Hidden
Markov Model of sequence and three-dimensional structural
analysis, Merm1 has been categorized into the seven--strand
family ofmethyltransferases, which includes the argininemeth-
yltransferase family (including CARM1, PRMT1) and the non-
SETdomain lysinemethyltransferases (includingDOT1L) (23).
Although there is strong evidence implicating the arginine
methyltransferases, and the SET domain methyltransferases in
regulating access of nuclear receptors to target sites and also in
mediating their effects on gene expression, little is known of
how the non-SET domain lysine methyltransferases regulate
nuclear receptor function (24). However, recent studies have
shown that H3K79 methylation, which is catalyzed by the non-
SET methyltransferase DOT1L, is regulated by cell cycle pro-
gression (25).
More recently Merm1 was identified in a genetic screen for
genes promoting cancer metastases by inhibiting Zac1-medi-
ated p53-dependent apoptosis (26). This action requiredmeth-
ylation of histone H3 lysine 9 (H3K9) at the Zac1 locus, thereby
rendering a transcriptionally repressive chromatin environ-
ment. However, Merm1 did not methylate H3K9 in vitro.
Here we show that Merm1 regulates GR binding to its
response elements and mediates subsequent H3K4Me3 gener-
ation, a mark found on active promoters. Interactome analysis
reveals Merm1 binding with histone-associated proteins and
protein kinases, intimating a pivotal role for the protein in sig-
nal/response coupling in chromatin modeling. Moreover,
Merm1 expression was repressed by a combined TNF/IFN
proinflammatory environment through an ubiquitination -de-
pendent mechanism, resulting in impaired GR function.
Importantly, high level Merm1 expression was found in the
bronchial epithelium but was significantly impaired in a broad
range of pulmonary inflammatory and neoplastic diseases.
EXPERIMENTAL PROCEDURES
Plasmids—TAT3-Luciferase (Luc), which contains three
copies of the glucocorticoid response element (GRE) from the
tyrosine aminotransferase plasmid, was a kind gift from Profes-
sor Keith Yamamoto (University of California, San Francisco).
The NRE-Luc reporter construct contains five copies of an
NF-B response element (Stratagene, La Jolla, CA). The human
wild-type WBSCR22/Merm1 cDNA cloned into cmv.SPORT6
was obtained fromThermo Scientific, Open Biosystems. Three
Merm1 deletion constructs were created;MethT, which lacks
amino acids (aa) 18–38, SAM, which lacks AA 39–200, and
NL, which lacks aa 266–281, were constructed from the wild
type by site-directed mutagenesis. The GRIP1 expression vec-
tor, in pcDNA3 was kind gift from Dr. Julie Stimmel (Glaxo-
SmithKline, Research Triangle Park, NC). Renilla luciferase
plasmid was used to correct for transfections efficiency (Pro-
mega, Southampton, UK). Halo-tag GR and Merm1 were con-
structed by cloningGR cDNA into the pFN21AB9466N-termi-
nal vector (Promega). A human mineralocorticoid receptor
expression vector was constructed by inserting human miner-
alocorticoid receptor cDNA into a pcDNAI backbone. Human
progesterone receptor B (PRB) and androgen receptor cDNAs
cloned into PCR3.1were kind gifts from theNancyWeigel Lab-
oratory, Baylor College of Medicine (Houston, TX).
Antibodies—The following antibodies were used: anti-GR and
anti-GRIP1 (BD Biosciences); anti-GR (rabbit, H300 Santa Cruz
Biotechnology); anti-GR (rabbit, Novus Biological); anti-Merm1
(WBSCR22) (mouse, Abcam); anti-Merm1 (WBSCR22) (rabbit,
SourceBioscience); anti-histoneH3acetyl (rabbit,Millipore); anti-
histone H3 lysine 4 trimethyl (rabbit, Millipore) and anti-histone
H3 lysine 79 dimethyl (rabbit,Millipore); anti-pan-methyl histone
H3 (Lys-9) antibody (rabbit, Cell Signaling); anti-TFIIB (rabbit,
Santa Cruz Biotechnology); horseradish peroxidase-conjugated
anti-mouse and anti-rabbit from GE Healthcare. Anti-Halo-tag
antibody (Promega). Mouse IgG and rabbit IgG were fromMilli-
pore. Fluorophore-conjugated (Alexa Fluor 546 and 488) anti-
mouse and anti-rabbit antibodies were from Invitrogen.
Cell Culture—Human epithelial carcinoma (HeLa), human
embryonic kidney cells (HEK293), and human lung carcinoma
(A549) cells were obtained from the European Collection of
Cell Cultures (Salisbury, UK) and maintained in DMEM sup-
plemented with GlutaMAX I and 10% FBS (Invitrogen) in a
humidified atmosphere of 5% CO2 at 37 °C.
Reporter Gene Assay—Cells were transfected with 1.2 g of
Merm1, GRIP1, or cmv.SP6 plasmid, 2 g of firefly luciferase
(TAT3-Luc), and 0.5 g of Renilla luciferase reporter using
FuGENE 6 (Roche Diagnostics). After 24 h, cells were trans-
ferred tomedium containing charcoal dextran-stripped serum,
treated as specified under “Results,” and then assayed for lucif-
erase activity following the manufacturer’s instructions (Pro-
mega). To control for transfection efficiency, cells were taken
from a single pool and divided into different treatment condi-
tions. All firefly luciferase reading were normalized to Renilla
luciferase.
Small Interfering RNA (siRNA) Transfection—HeLa cells
were transfected with either 10 nMMerm1 siRNA ID s41529 or
Merm1 siRNA ID s41530, with appropriate control siRNA 10
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nM All Stars Negative Control siRNA (#1027281, Qiagen,
Valencia, CA) or Dharmacon siCONTROL Nontargeting
siRNA, respectively. Transfection was achieved using Lipo-
fectamine RNAiMax (Invitrogen) or Dharmafect1 (Thermo
Scientific) in accordance with the manufacturer’s instructions.
48 h later cells were treated as specified under “Results” and
processed accordingly.
Quantitative RT-PCR—After siRNA and Dex treatment,
total RNAwas prepared fromHeLa cells using the RNeasymini
kit with on-columnDNase I digestion (Qiagen), and cDNAwas
synthesized using a High Capacity RNA to cDNA kit and ana-
lyzed using the Power SYBR Green PCR Master Mix (Applied
Biosystems). A panel of seven GC target genes was selected
from our previous microarray expression studies (27). Quanti-
tative RT-PCR primer sequences are available on request.
Expression levels were calculated using the comparative Ct
method, normalizing to the GAPDH control.
Western Blotting—Cells were treated as specified under
“Results” and lysed in NETN buffer (0.5% Nonidet P-40, 1 mM
EDTA, 50 mM Tris-Cl, pH 8.0, NaCl (120 mM) containing pro-
tease (Calbiochem) and phosphatase inhibitors (Sigma). Pro-
teins were separated by SDS gel electrophoresis and transferred
to 0.2 M nitrocellulose membranes (Bio-Rad) overnight at
4 °C. Membranes were blocked for 6 h (0.15 M NaCl, 1% milk,
and 0.1% Tween 20) and incubated with primary antibodies
(diluted in blocking buffer at 1 in 1000) overnight. After 3
washes (88 mM Tris, pH 7.8, 0.25% dried milk, and 0.1% Tween
20), membranes were incubated with a species-specific horse-
radish peroxidase-conjugated secondary antibody (in wash
buffer) for 1 h at room temperature and washed an additional
three times, each for 10 min. Immunoreactive proteins were
visualized using enhanced chemiluminescence (ECL Advance,
GE Healthcare).
Immunofluorescence—Cells were treated as specified and
fixed with 4% paraformaldehyde for 10 min at room tempera-
ture and permeabilized (0.25% Triton X-100) for 5min at room
temperature. Fixed cells were blocked (3% serum from the spe-
cies secondary antibody was raised in) for 30 min and then in
primary antibody (diluted in blocking buffer) overnight at 4 °C.
After three 5-min washes in PBS, cells were incubated in the
secondary antibody for 2 h. After three further 5-min washes,
coverslips were mounted using Vectashield hard-set mounting
compound containing the nuclear DAPI stain (Vector Labora-
tories). Images were acquired on a Delta Vision RT (Applied
Precision, Issaquah, WA) restoration microscope using a60/
1.42 Plan Apo objective and the Sedat filter set (Chroma 89000;
Chroma Technology Corp., Rockingham, VT). The images
were collected using a CoolSNAP HQ (Photometrics, Tuscon,
AZ) camera with a Z optical spacing of 0.5 m. Images were
deconvolved using Softworx software, and maximum intensity
projections of images were processed using Image J.
Nuclear and Cytoplasmic Fractionation— Cells were col-
lected and resuspended in ice-cold buffer A (10mMHEPES, 1.5
mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.05% Nonidet P-40, pH
7.9) supplemented with a mixture of protease and phosphatase
inhibitors. Cells were then centrifuged for 10 min at 2000 rpm
(291 g). The supernatant was stored as the cytosolic fraction.
The pellet was then resuspended in buffer B (5 mM HEPES, 1.5
mMMgCl2, 0.2mM EDTA, 0.5mMDTT, 26% glycerol (v/v), 300
mM NaCl, pH 7.9) supplemented with protease and phospha-
tase inhibitors. The samples were incubated on ice for 30 min
before centrifugation at 24,000  g for 20 min at 4 °C. The
supernatant was kept as the nuclear fraction.
Chromatin Immunoprecipitation (ChIP)—For the ChIP
assays, cells were grown to a final density of 1  106 and
treated as indicated in the figure legends. ChIP assays were
performed as previously described (28, 29). Chromatin was
sheared by sonication and size-fractionated to ensure fragmen-
tation to between 200 and 400 bp. For immunoprecipitation,
chromatin was incubated with 3 g of nonspecific IgG or spe-
cific antibody at 4 °C overnight. Primers used in the ChIP assay
are shown in the supplemental Materials and Methods. Input
and immunoprecipitated DNA samples were analyzed and
quantified by PCR and gel electrophoresis and by quantitative
PCR. Real-time PCRs were carried out in triplicate on each of
the immunoprecipitated and input DNA sample. Results are
expressed as percentage enrichment relative to input chroma-
tin. Each ChIP experiment was repeated on three occasions,
and the mean S.D. are shown.
Affymetrix Gene Arrays—Human expression data along with
accompanying sample descriptions (cell populations are all
greater than 95%pure)were purchased fromGeneLogic (Gene-
Logic Division, Ocimum Biosolutions, Inc.) in 2006 and later
organized by sample type. Human tissue samples were col-
lected surgically from anonymous donors under Institutional
Review Board-approved informed consent. In all cases samples
were processed according to rigorous freezing and processing
protocols to ensure preservation of RNA and transported to
Gene Logic Inc. Clinical medical records were accessioned,
reviewed, and entered intoGene Express software to provide a
searchable database of combined clinical, pathological, and
gene expression information. Independent pathologists at
Gene Logic reviewed each specimen microscopically and
required each to be diagnostically accurate for its acceptance
and inclusion in the database. Classification as normal was
defined as no histopathological abnormality in the tissue under
study and no clinical (physical or laboratory finding) abnormal-
ity associated with the tissue under study. The tissue type was
determined by the surgical pathology report and confirmed
microscopically. Expression data for each sample had been
determined using mRNA amplification protocols as recom-
mended by Affymetrix (Affymetrix, Inc.) and subsequent
hybridization to the Affymetrix U133_plus2 chip. Purchased
data were subject to reported quality control measures includ-
ing minimal 5/3 ratios for -actin and GAPDH as well as
maximal scale factors as reported by Affymetrix MAS 5.0.
Expression data were normalized using MAS5.0 with a target
intensity of 150.
Human Embryos—Human embryos were collected with
informed consent after ethical approval from the North West
Regional Ethics Committee, UK (08/H1010/28) after medical
or surgical termination of pregnancy and staged immediately
by stereomicroscopy according to the Carnegie classification.
The collection, use, and storage of material followed guidelines
from the UK Polkinghorne Committee, legislation of the
Merm1Mediates Glucocorticoid Resistance
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Human Tissue Act 2004, and the Codes of Practice of the
Human Tissue Authority, UK.
Immunohistochemistry—Paraffin embedded sections were
rehydrated (xylene 3 min, 100% for ethanol 2 min, 90% ethanol
for 2 min, and a rinse in water), and endogenous peroxidase
activity was quenched after a 20-min incubation with H2O2
(0.1%). After three 5-min washes in PBS antigen was retrieved
by boiling in sodium citrate buffer for 20 min, then washed a
further 3 times (PBS, 5 min each). Sections were incubated in
primary antibody (PBS, 3% goat serum, 0.1% Triton X-100)
overnight at 4 °C in a humidified container. After three 5-min
washes in PBS, slides were incubated in secondary antibody
(1:800 dilution; PBS, 0.1% Triton X-100) for 2 h at 4 °C in a
humidified container. After three 5-min washes in PBS, sec-
tions were incubated with streptavidin-HRP (1:200; PBS,
0.1% Triton X-100) for 1 h at 4 °C in humidified container
and washed a further three times (PBS, 5 min each). Positive
immunoreactivity was visualized using 3,3-diaminobenzi-
dine (brown) and nuclei-counterstained with toluidine blue.
After a brief wash in PBS, sections were dehydrated (rinse
water, 10 s of 70% ethanol, 10 s of 90% ethanol, 3 min of 100%
ethanol, 2 min of xylene, 2 min of xylene, 30 s air dry) and
mounted using Entellan (Merck Millipore, Intl.). Imaging
was performed using an Axioscope Imager A.1 and Axiovi-
sion 4.7.1 imaging software (Zeiss).
Lung Tissue Array—Human lung disease spectrum tissue
array (LC487) was purchased from Insight Biotechnology. The
tissue array comprised paraffin-embedded sections (5 m
thick) with duplicate cores per case with two normal lung tis-
sues, one adjacent normal lung tissue, three each of lung hyper-
plasia of stroma and pulmonary fibrosis with chronic inflam-
mation of bronchiole, one each of lung lobar pneumonia,
pulmonary atelectasis, and collapse of lung, two each of pulmo-
nary tuberculosis, pulmonary emphysema, and inflammatory
pseudotumor plus one lung small cell carcinoma, two lung ade-
nocarcinomas, and three lung squamous cell carcinomas. Lung
sections were processed for immunohistochemistry and
stained with anti-Merm1 antibody (rabbit, Source Bioscience;
1:100), and representative images were taken for each core.
Four separate images of each section were given a score (1–4)
by three independent masked observers. Average scores were
calculated and then combined according to pathology.
Co-immunoprecipitation ofMerm1 and GR Complexes—A549
cells were harvested and homogenized in lysis buffer (20 mM
HEPES-KOH, pH 7.4, 0.1 M potassium acetate, 2 mM MgCl2,
0.1% Tween 20, 1 M ZnCl2, 1 M CaCl2, 0.5% Triton X-100,
250 mM NaCl, 250 units/sample DNase (Novagen), 1/100 (v/v)
protease and phosphatase inhibitor cocktails (Roche)) and cen-
trifuged at 8000 g for 10 min at 4 °C. Lysates were cleared by
centrifugation at 13,000 g at 4 °C and incubated with anti-GR
antibody (BD Bioscience) for 1 h at 4 °C. The immunoprecipi-
tation was then performed by incubating cell lysates for 30 min
at 4 °C with 10 l/sample of Dynabeads M-280 sheep anti-
mouse IgG (Invitrogen). After 3 more washes in lysis buffer,
proteins were eluted in NuPAGE LDS sample buffer (4)
(Invitrogen) containing 100 mM DTT (Invitrogen) and incu-
bated for 10 min at 70 °C. Immunoprecipitated proteins were
either frozen at 20 °C or used for immunoblot analysis (as
described above) using antibodies against GR, phosphorylated
GR, and Merm1.
Analysis of Merm1 Interacting Proteins—Halo-tag Merm1
constructs were generated from the Merm1-SP6 plasmids
according to the manufacturer’s instructions (Promega).
HEK293T cells were seeded in 20  150-mm dishes, 15 g of
Merm1 (N-terminal Halo-tag), or 15 g of Halo control plas-
mid, and 45 g of polyethyleneimine were added to each dish
and left for 24 h. The cells (108) were washed in PBS and then
lysed in Halo lysis buffer (150 mM NaCl, 0.5% Triton X-100, 3
mMMgCl2, 20 mM Bicine, 1MCaCl2, and 1M ZnCl2, pH 7.4,
protease inhibitor, and phosphatase inhibitor. The lysate was
passed through a 23-gauge needle and then treated with 100
units of DNase (Promega) for 20 min. The cell lysate was
cleared and incubated with Halo-link resin (75 l/ml, pre-
washed with (TBS) and 0.05%CA-630 (TBS CA-630) overnight
(4 °C). The resin was washed 6 times with TBS CA-630, trans-
ferring the resin to a new microtube between each wash. The
resin was resuspended in 30 l of TBS CA-630 with 30 units of
tobacco etch virus (TEV) protease and incubated for 2 h on ice,
after which 10 l of 4 SDS (1% SDS and 50 mM Tris-HCL)
elution buffer was added. 10 l of NuPAGE LDS loading buffer
and 6 l of 1 M dithiothreitol was added. Samples were sub-
jected to electrophoresis, and subsequent gels were stained
with Simply Blue Coomassie safe stain. Protein bands were
excised and destained with repeated incubation in 200 mM
ammoniumbicarbonate, 40% (v/v) acetonitrile. Gel pieces were
dried with 3 washes in 100% acetonitrile and then trypsinized
(trypsin resuspended in 100 mM ammonium bicarbonate, 5%
(v/v) acetonitrile) overnight at 37 °C. Peptides were extracted
from the gel pieces by incubation in 50% (v/v) acetonitrile, 0.1%
(v/v) formic acid, and peptides were desiccated and resus-
pended in 3% (v/v) acetonitrile, 0.1% (v/v) formic acid, 20 mM
citric acid, pH 2.7. For each analysis, 10% of the peptide sample
was loaded onto a nanoACQUITY UPLC Symmetry C18 Trap
(5 m, 180 m 20 mm), and flow was set to 15 l/min of 3%
(v/v) acetonitrile, 0.1% (v/v) formic acid, and 20 mM citric acid
for 5 min. Analytical separation of the peptides was performed
using a nanoACQUITY UPLC BEH C18 column (1.7 m, 75
m 250mm). Briefly, peptides were separated over a 91-min
solvent gradient from 3% (v/v) acetonitrile, 0.1% (v/v) formic
acid to 40% (v/v) acetonitrile, 0.1% (v/v) formic acid on-line to a
LTQ Orbitrap Velos (Thermo). Data were acquired using an
information-dependent acquisition method where, for each
cycle one full MS scan of m/z 300–1700 was acquired in the
Orbitrap at a resolution of 60,000 atm/z 400 with an automatic
gain control target of 106. Each full scan was followed by the
selection of the 20 most intense ions; CID (collision-induced
dissociation) and MS/MS analysis was performed in the LTQ
Orbitrap velos. Selected ions were excluded from further anal-
ysis for 60 s. Ions with an unassigned charge or a charge of1
were rejected.
Data were analyzed using Mascot (Matrix Sciences); the
parameters were: Uniprot database, taxonomy Homo sapiens,
trypsin with up to 1 missed cleavage allowed, variable modifi-
cations oxidized methionine, phosphorylated serine, threo-
nine, and tyrosine and the peptide tolerance of 0.025 and 0.03
Da for MS/MS tolerance. A functional annotation of interact-
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ing proteins was carried out using theDAVID software package
(Version 6.7).
Statistical Analysis—Data were expressed as the means 
standard deviation and compared using the SPSS software
package (Version 16, SPSS Inc., Chicago, IL). Multiple means
were compared by one-way ANOVA followed by the Bonfer-
roni post hoc test, Tukey’s test, or Kruskal-Wallis test, and for
comparison of two groups, Student’s t test or the Mann Whit-
neyU test (with a Bonferroni correction where appropriate) for
independent samples was used. p 0.05 was considered statis-
tically significant.
RESULTS
Merm1 Regulates GR Transactivation—We have previously
used a stratified screening approach to identify genes capable of
modulating GR function (27, 30). Here, we profiled Merm1
because of its putative action as a histonemethyltransferase and
its action as a transcriptional co-repressor (26). Unexpectedly,
we found that overexpression ofMerm1 (Fig. 1,A andB) poten-
tiated GR transactivation of a TAT3-Luc reporter gene in a
similar manner to GRIP1 (Fig. 1A). Merm1 protein was found
to be endogenously expressed in HeLa cells (Fig. 1B), permit-
ting analysis of cellular distribution and trafficking (Fig. 1, C
and D). Merm1 localization was initially studied using bio-
chemical means in fractionated cells with -actin as a cytoplas-
mic and TFIIB as a nuclear marker. Merm1 was distributed in
both nuclear and cytoplasmic compartments and showed no
alteration in distribution with GC treatment, although as
expected the GR accumulated in the nucleus of treated cells
(Fig. 1C).
Further analysis of Merm1 distribution using immunofluo-
rescent approaches supported the subcellular fractionation
results (Fig. 1D). AgainMerm1was seen through both cytoplas-
mic and nuclear compartments, with no change seen after GC
treatment. GR translocation was observed as expected, serving
as a useful internal control (Fig. 1D). The overlay pictures show
stronger overlap ofMerm1 andGRdistributions afterGC treat-
ment, as evidenced by the increase in yellow immunofluores-
cence (Fig. 1D, right panels).
GR transrepression was investigated using a TNF-activated
NF-B reporter gene in HeLa cells. In this model TNF drives
activation of an NF-B reporter gene, and this induction is
repressed by activated GR. Neither Merm1 nor GRIP1 affected
GR transrepression under these conditions (supplemental Fig.
S1). Merm1 potentiated transactivation by the related miner-
alocorticoid receptor, progesterone receptor, and androgen
receptor on the same TAT3-Luc reporter gene when trans-
fectedwith the appropriate nuclear receptor expression vectors
in the nuclear receptor-deficient cell line HEK293T (supple-
mental Fig. S2). This observation demonstrates broad Merm1-
mediated steroid receptor co-activation.
Functional Domain Analysis of Merm1 for Regions Responsi-
ble for Potentiating GR Transactivation—Merm1 contains a
highly conserved methyltransferase domain (MethT), an S-ad-
enosyl-L-methionine (SAM) domain, and a nuclear localization
signal (NLA) domain (31) (Fig. 1E and supplemental Fig. S3). To
determine which of the functional domains is responsible for
the potentiation of GR transactivation, deletion constructs
were generated in which individual functional domains (as
indicated in Fig. 1E) were deleted. The Merm1 NL construct
still potentiated the glucocorticoid-induced transactivation in
HeLa (p 	 0.001) cells, whereas deletion of either the SAM or
MethT domains abolished the co-activation function of
Merm1. Expression of the mutated constructs was analyzed by
immunoblotting (supplemental Fig. S3). The SAM domain
mutant is heavily truncated and may not be detected by the
Merm1 antibody (raised against amino acids 1–263 (Fig. 1E and
supplemental Fig. S3).
Merm1 Is Widely Expressed, Showing High Levels of Expres-
sion in Bronchial Epithelium and Transcript Induction in Acti-
vatedCD8TandBLymphocytes—Toguide further the inves-
tigation of Merm1 function, we determined Merm1 tissue
distribution using Affymetrix array profiles of normal human
tissue. These databases were derived from human tissue sam-
ples, collected under standardized conditions, and analyzed by
Affymetrix gene arrays. Interrogation of these databases
revealed near ubiquitous Merm1 expression, but a striking
finding was greatly increased expression in human bronchial
brushings, a mixture of cell types that line the major airways
including ciliated epithelial cells, Clara cells, goblet cells, and
airway resident macrophages (Fig. 2A). To determine if this
pattern of gene expression resulted in a distinct pattern of
Merm1 protein expression, we analyzed human fetal lung tis-
sue. Expression of Merm1 protein (brown) was seen to be most
obvious in the developing bronchial lumen lining cells (Fig. 2B),
a result compatible with the gene expression data above (Fig.
2A). By comparison, expression of GR protein was seen more
diffusely through the lung architecture (Fig. 2C). Use of IgG
controls revealed negligible background staining (Fig. 2D). As
inhaled GC is a widely used intervention for inflammatory lung
disease but suffers from a wide variation in response, we meas-
ured Merm1 expression and regulation in a variety of relevant
immune cell types under basal and activated conditions (Fig. 2,
E and F). Again, we interrogated commercially available
Affymetrix gene expression databases (see “Experimental Pro-
cedures”). Primary human immune cells were purified from
blood or lung (as indicated) and verified to be at least 95% pure
based on analysis of cell surface markers. Cells were activated
by the indicated stimuli and time before analysis.
The most striking feature seen was augmented Merm1 tran-
script abundance in CD8 T lymphocytes and B lymphocytes
when activated with the classical stimuli CD3 for CD8 T and
CD40 ligand and B cell receptor antibody for B lymphocytes
(Fig. 2, E and F). Merm1 expression in macrophages, either
monocyte-derived macrophages (MØ) or alveolar macro-
phages (ALV MØ), was not affected by activation with LPS
(Fig. 2F).
Analysis of the Merm1 Protein Interactome—To assist in
determining themechanism ofMerm1 co-activation of theGR,
wemapped theMerm1 interactome, analyzing purifiedMerm1
complexes by mass spectroscopy (Fig. 3). To generate a robust
and clean Merm1 bait, we used a Halo-tagged Merm1
expression cassette. The Halo-tag (Fig. 3A) is recognized by
an immobilized ligand, thereby capturing Merm1 complexes
for proteomic analysis. This offers advantages over antibody
purification protocols by minimizing off-target protein cap-
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ture. All analyses were controlled using the Halo-tag alone to
permit subtraction of proteins recognizing the epitope tag.
The Halo-tagged Merm1 was transfected into HEK293T
cells, which offer high transfection efficiency and high trans-
fected protein expression. The cellular expression of Halo-
taggedMerm1was verified using an immunoblot of transfected
cells (Fig. 3B, input lane) and the successful cleavage of the
Halo-tag by use of the TEV from the pulldown material (PD),
and thereby enrichment of Merm1 protein was also confirmed
by immunoblot (Fig. 3B, PDTEV lane).
Purified Halo complexes (Halo-tag alone or Halo-Merm1)
were resolved by SDS-PAGE (Fig. 3C) and subject to mass
spectroscopy protein identification. Proteins identified by
that were unique for the Halo-Control (n 
 31), Halo-
Merm1 (n 
 169), and proteins enriched under both condi-
tions (n 
 21) (Fig. 3D).
FIGURE 1.Merm1 enhances GR-mediated transactivation via its SAM andmethyltransferase domains. A, HeLa cells were transfected with 2g of firefly
luciferase (TAT3-Luc) and0.5gof Renilla luciferase reporterwithoneofMerm1,GRIP1, or cmv.SP6plasmid (1.2g) as indicated and incubatedwith 10nMDex
for 24 h before luciferase assay. Graphs depict the means S.D. of triplicate wells from three independent experiments. Data were compared using one way
ANOVA followed by Bonferroni’s post hoc test. B, cell lysates prepared from Awere used to confirm induction of Merm1 expression. Cell lysates were resolved
by SDS-PAGE, and after transfer to nitrocellulose membranes were analyzed with a specific Merm1 antibody, and tubulin was used as a loading and transfer
control. C, HeLa cells were treatedwith either vehicle or 100 nMDex for 1 h. Theywere then lysed and separated into cytosolic (Cyt) and nuclear (Nuc) fractions.
Cellular fractions were separated by gel electrophoresis and immunoblotted using antibodies against -actin (cytosol), TFIIB (nuclear), GR, and Merm1.
Experiments were repeated three times with similar results. D, HeLa cells were treated with vehicle (Veh) or 100 nM Dex for 1 h, then fixed and labeled with
antibodies specific to Merm1 (green) and GR (red). Representative images are shown. Scale bar, 50 m. E, HeLa cells were transiently co-transfected with the
TAT3-Luc reporter gene, Renilla control plasmid, and the indicatedMerm1expressionplasmids (wild type,MethT,SAM,NL). Diagrammatic representation
of Merm1 protein and its functional domains (with amino acid numbers) is shown. Within the indicated SAM domain is a highly conserved DXGXGXGXXG-like
motif where Xmay be any amino acid, and D and G are aspartic acid and glycine, respectively. NLS, nuclear localization signal. The graphs showmean S.D.
of triplicatewells. Experimentswere repeatedon threeoccasions.RLU, relative light unit; ***,p	0.001. Analysis byANOVAwas followedby theBonferroni test.
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Previous studies had failed to detect intrinsicMerm1 histone
methyltransferase activity in reconstituted in vitro assays. We
were also unable to detect direct histone methyltransferase
activity and postulated a requirement for additional, unknown
cellular components for Merm1 catalytic action (26). We did
not detect an interaction between GR and Merm1, which may
reflect the sensitivity limits of our proteomics technology but
may also result from low level GR expression in HEK293T.
Therefore, we sought evidence of interaction using immuno-
precipitation-immunoblotting in A549 cells (Fig. 3E). As dem-
onstrated above, A549 cells express endogenous GR and
Merm1 and, moreover, possess the machinery to permit
Merm1 co-activation of the GR. Immunoprecipitation of GR
from vehicle and GC-treated A549 cells was successful, and
althoughMerm1 was seen in the input cell lysate no detectable
band was seen in the GR immunoprecipitate (Fig. 3E). This
FIGURE 2.Merm1expression in normal human tissues. A, the expression ofMerm1wasmeasured in a profile of normal human tissue samples acquired and
analyzedbyAffymetrix gene array. Samplepreparation andanalysis is describedunder “Experimental Procedures.” Independent sampleswereused: bronchial
brushings
 7; lung
 100; spleen
 31; adipose
 113; thymus
 67; liver
 32; bone
 12. Analysis was carried out using a one-way ANOVA, with Tukey’s
post-hoc test (*, p 	 0.05). B–D, Merm1 and GR expression in human fetal lung. Normal, human fetal lung explants were prepared, fixed, and analyzed by
immunohistochemistry. Antibody bindingwas disclosed by 3,3-diaminobenzidine staining (brown), with nuclei counter-stainedwith toluidine blue. E, Merm1
gene expression in hematopoietic cells. Human Affymetrix gene expression databases (see “Experimental Procedures”) were interrogated for Merm1 expres-
sion. Independent samples were analyzed; n 
 4, except alveolar macrophages, n 
 5, and macrophages, n 
 9. *, p 	 0.05 one way ANOVA followed by
Bonferroni test. F, Merm1 expression in stimulated hematopoietic cells. Human Affymetrix gene expression databases (“Experimental Procedures”) were
interrogated forMerm1 expression. CD4 andCD8 lymphocyteswere stimulatedwith anti CD3 (n
 4 for each group),macrophages (MØ)were stimulatedwith
LPS (6 h treatment) (n 
 9 for each group); alveolar macrophages (Alv MØ) were unstimulated (n 
 5) and stimulated with LPS (6 h n 
 15); B cells were
stimulated with CD40 ligand (1), anti-B cell receptor antibody (2), or both (48 h treatment) (n 
 4 for each group). ***, p 	 0.001, one-way ANOVA, with
Bonferroni post-hoc test; NS, not significant.
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FIGURE 3. Analysis of the Merm1 interactome. A, the Halo-tag is a 34-kDa protein tag from dehalogenase (Rhodococcus sp.) which binds to its ligand
covalently. Halo-Merm1 is captured with the Halo-link resin. Merm1 is cleaved from the Halo ligand (leaving the Halo-tag on the resin) complex using
a TEV protease, which targets a protein sequence at the linker as indicated. Eluted proteins were then analyzed by SDS-PAGE and mass spectrometry.
Immunoblots showing Halo-control and Halo-Merm1 expression in HEK cells; PDTEV (pull down and TEV) refers to the sample after it had been bound
to the Halo-link resin, washed, and treated with the TEV protease. Approximately 1% of the sample was loaded for immunoblot. The same process was
performed for the Halo-control protein. B, Halo-Merm1-transfected cell lysate (Input) and eluate after Halo-resin purification of the transfected cell
lysate and subsequent TEV cleavage (PDTEV) were resolved by SDS-PAGE and immunoblotted (IB) for Merm1. The migration of Halo-tagged Merm1
and full-lengthMerm1 are indicated (based onmolecular weight and antibody reactivity). C, HEK293T cells were transfected in bulk to permit proteomic
analysis of Merm1 interacting proteins. For both Halo control and Halo-Merm1, 10  15-cm dishes in total were transfected before being pooled for
analysis. Proteins eluted from the Halo resin post cleavage with TEV were resolved by SDS-PAGE, and the gels were stained with Coomassie Blue.
Molecular mass marker migration is indicated. D, proteins identified by mass spectrometry that were unique for the Halo control (n
 31), Halo-Merm1
(n
 169), and proteins enriched under both conditions (n
 21) (using the ensembl gene ID) are presented in Venn diagram. E, A549 cells were treated
with either vehicle or 100 nM Dex for 1 h. Cells were lysed and immunoprecipitated (IP) with antibodies against GR. Mouse IgG was used as the control
for the IP assay. Precipitates were immunoblotted for GR, and Merm1. F, A549 cells were transfected with 0.4 g/ml Halo-tag-GR or Halo-tag control
vector. A549 cells were treated with vehicle or 100 nM Dex for 1 h and then lysed and bound to Halo link resin. The Halo-tag was removed as described
above. Precipitates were immunoblotted for GR andMerm1. Input lanes reveal slowermigration of the Halo-tagged GR.G, as E, but immunoprecipitation
using a GRIP1 antibody. Immunoprecipitates were analyzedwith antibodies to GRIP1, andMerm1.H, Merm1 interacting proteins were analyzedwith the
DAVID bioinformatics software (Version 6.7); the top 12 gene ontologies (GO term) are shown as is the p value (shown asLog). A list of notable Merm1
interacting proteins was manually curated (see supplemental Table 1 for full details).
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provides additional evidence that Merm1 does not physically
bind to GR, but in a further attempt to detect interaction we
used a Halo-GR fusion protein as bait. A549 cells were trans-
fected with a Halo-GR expression vector, and Halo complexes
were purified as above. Both endogenous GR and Halo-GR
were detectable in the input samples (Fig. 3F, input lanes). After
TEV cleavage, abundant full-length GR was seen in the eluate
(Fig. 3F, TEV protease lanes).
The lack of evidence to support an interaction between GR
and Merm1 suggested an indirect mechanism of regulation. A
strong candidate is the GR co-activator and scaffold protein
GRIP1/SRC2. Therefore, we performed immunoprecipitation-
immunoblot studies in A549 cells with GRIP1.We were able to
enrich GRIP1 in cell lysates under vehicle and GC-treated con-
ditions (Fig. 3G) and were also able to detect a weak interaction
with Merm1 as detected by blotting the immunoprecipitate
(Fig. 3G).
Among the interacting partners we identified (Fig. 3H, sup-
plemental Table 1 and supplemental data) were proteins with a
functional role for Merm1 in driving histone modification and
ribosome biogenesis (32), including the histone-binding pro-
tein RBBP7, which binds H3K4 in a methylation-dependent
manner (33), and RUVBL1 and -2, which are both components
of the NuA4 and INO80 complexes (Fig. 3H and supplemental
Table 1). Merm1 was also found with ubiquitin protein ligases,
and in addition, ubiquitin was found in the protein complex,
suggesting a potential mechanism for regulating Merm1 pro-
tein levels by ubiquitinylation and degradation by the 26 S pro-
teasome. Many of the identified Merm1 interacting proteins
contribute to ribosome biogenesis, as shown in the top 12 gene
ontologies (Fig. 3H). We also found TRMT112, the human
homologue of TRM112, which has been shown to be essential
for the stability of the yeastWBSCR22homologue (Bud23) (34).
Merm1 Alters GR Target Gene Expression by GR-dependent
and -independent Mechanisms—To identify endogenous gene
targets for Merm1, siRNA knockdown was used in A549 cells.
Merm1 expression was virtually abolished by siRNA (Fig. 4A).
Seven glucocorticoid-regulated genes (27)were selected for ini-
tial analysis. Merm1 knockdown augmented base-line expres-
sion of one of the seven genes, interleukin-6 signal transducer
(IL6ST) (Fig. 4B). TSC22 domain family 3 (GILZ, TSC22D3)
and FK506-binding protein 5 (FKBP5) were not regulated by
Merm1 loss alone, but in the absence of Merm1 both FKBP5
and GILZ were significantly less responsive to GR induction
(Fig. 4C). For both genes, again, loss of Merm1 had no effect on
basal expression (Fig. 4C).
In addition to these effects onGR transactivated target genes,
we analyzed three proinflammatory cytokine/chemokine
genes: interleukin 6 (IL6), interleukin 8 (IL8), and chemokine
FIGURE4.Merm1affectsGRregulationofendogenousgenes.A, HeLa cells
were transfected with either 10 nM Merm1 or control siRNA for 48 h before
immunoblotting forMerm1and-tubulin. Representative images are shown.
B, HeLa cells were transfectedwith 10 nMMerm1or control siRNA as inA. Post
lysis RNA was purified, and quantitative RT-PCR was used to measure basal
expression of seven endogenous index glucocorticoid-regulated genes
(aspartate hydroxylase (ASPH), FK506-binding protein 5 (FKBP5), metalloth-
ionine 1X (MT1X), interleukin-6 signal transducer (IL6ST), myosin 1 (MYO1B),
glutamate ammonia ligase (GLUL), and glucocorticoid leucine zipper (GILZ)).
Experimentswere performed in triplicate on three occasions. Data presented
are the mean  S.D., and analysis in one way ANOVA was followed by Bon-
ferroni tests. **, indicates p	 0.01 comparedwith control siRNA. C, HeLa cells
were transfectedwith 10nMMerm1or control siRNA for 48hand then treated
with vehicle or 100nMDex for 6 hbefore lysis andRNAextraction. The expres-
sion of index, endogenous GR target genes GILZ, FKBP5, IL6, IL8, and CCL2
was measured by quantitative RT-PCR. Gene expression is expressed as -fold
change. For inducedgenes thepostDexexpression is dividedby thenegative
control (ve). For repressed genes the control expression is divided by the
post Dex expression (shown as a negative number). On the left all the data
are expressed relative to the control siRNA, vehicle-treated group, and on the
right the same data are plotted to show the effect of Dex as a -fold change
under control siRNA or specific Merm1 siRNA-treated conditions. Graphs
show the mean  S.D. of experiments performed in triplicate and are
repeated three times. **, p 	 0.01; ***, p 	 0.001, analysis was by one way
ANOVA and post hoc Bonferroni tests.
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(C-C motif) ligand 2 (CCL2) (Fig. 4C). Even in the absence of
cell activation GC treatment significantly inhibited expression
of all three genes (Fig. 4C).
Loss of Merm1 expression alone reduced expression of IL-6,
suggesting coordinate regulation of the IL-6 autocrine circuit,
as the IL6 signal transducer is induced byMerm1 loss (Fig. 4, B
and C). In contrast, IL8 and CCL2 were unaffected by loss of
Merm1 under basal conditions (Fig. 4C, left panels). However,
loss of Merm1 impaired glucocorticoid-repression of both IL6,
and IL8, but had no effect onCCL2 (Fig. 4C, left panels). Impor-
tantly, Merm1siRNA did not affect GR expression (Fig. 5A). As
a further control for the specificity of the Merm1 siRNA, we
FIGURE 5.Merm1andGRChIP to the same regionofGILZpromoter and regulates histonemethylation.A, HeLa cellswere grownand transfectedwith 10
nM Merm1 specific siRNA (Merm1 siRNA) or control siRNA (control) for 48 h. Cells were treated with either vehicle or 100 nM Dex overnight and then lysed and
immunoblotted forMerm1,GR, and-tubulin.B, schematic representationofGILZpromoter upstreamof transcription start site (TSS). Thegray boxes represent
the regions with GREs. GL-1, -2, and -3 are primer pairs used in the ChIP assay. GL-1 served as the non-GR binding (negative) control region for the ChIP assay.
GL2 and GL-3 contained 1 and 3 characterized GREs, respectively (31). The transcriptional start site is shown by the black arrow. C and D, control and
siRNA-mediatedMerm1 knocked-downHeLa cells were treatedwith vehicle or 100 nMDex for 1 h. Theywere then fixed using formaldehyde, and a ChIP assay
was performed using antibodies against GR, Merm1, and acetylated H3K9 and analyzed with primers for GL-3 (C) and GL-2 (D) promoter regions. E and F, ChIP
assays were performed using antibodies against H3K4me3, H3K79me2, and H3K9mewith primers for GL-3 (E) and GL-2 (F). Control andMerm1-specific siRNA
were used as indicated. Nonspecific rabbit andmouse IgGs were used as controls for the immunoprecipitation assay. The recovered chromatin fractions were
analyzed both by PCR and agarose gel electrophoresis and also by quantitative PCR for precise quantification. Results are expressed as a % enrichment of
recovered immunoprecipitated chromatin relative to the input sample. All ChIP assays were performed on three separate occasions using cells of different
passage before the data were pooled for analysis. Graphs show the mean S.D. **, p	 0.01 and ***, p	 0.001.
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used a different Merm1 siRNA, which caused a similar loss of
GR transactivation (supplemental Fig. S4–S6). This selectivity
of target gene regulation suggests a strong role for target gene
specific factors in conferringMerm1 co-modulation to the GR.
Merm1 and GR Locate to the Same Region of GILZ
Promoter—To determine howMerm1 regulates GR transcrip-
tional activity, we employed the well characterized “index” glu-
cocorticoid-regulated gene, GILZ. Crucially, GILZ gene
expression is not affected byMerm1 knockdown alone, and the
binding sites conferring GR transactivation have been previ-
ously mapped (35). We used the endogenous GILZ gene as a
template to analyze GR gene regulation, employing a ChIP
approach targeting the two characterized GR binding sites and
using the non-GR binding region around the transcription start
site (GL-1) as control (Fig. 5B and supplemental Fig. S7).
Under basal conditions neither GR norMerm1was bound to
GL-1. Merm1 was bound to GL-2 under basal and GC condi-
tions but was barely detectable on GL-3. GR loading on GL-2
and GL-3 regulatory regions was significantly increased by GC
(Fig. 5, C andD), with attendant induction of H3K9 acetylation
at both sites examined (Fig. 5, C andD). Knockdown ofMerm1
with siRNA resulted in a significant loss of GR loading onto
both the GILZ GREs (GL-2 and GL-3) as measured by quanti-
tative PCR of immunoprecipitated chromatin compared with
input (Fig. 5,C andD). Therewas detectableGR loading to both
GL-2 and GL-3 under basal conditions, and loss of Merm1
expression reduced this loading to a greater extent for GL-2
than GL-3. The functional significance of this low level GR
loading is unclear, but the small reduction in histone H3K9
acetylation seen at GL-2 supports a productive interaction with
GR at this locus even under ligand-free conditions, which is
dependent on Merm1.
Merm1 Modulates Histone Methylation in Response to GR
Activation—AsMerm1 has putative histone methyltransferase
activity, we analyzed histone H3 methylation in response to
activated GR (Fig. 5, E and F). After GC treatment, there was a
marked induction of the active promoter chromatin mark
H3K4me3 at GL-2 and GL-3 (Fig. 5, E and F) and reduction of
the elongation chromatin mark H3K79me2 (Fig. 5, E and F). In
addition, we documented a small, but significant induction of
the repressive mark H3K9me at GL-3 in response to GC (Fig.
5E), with no detectable H3K9me at GL-2 under any condition
examined. Overall the H3K4Me3 mark was dominant, with
near 15% enrichment compared with	5% for H3K79Me2 and
H3K9me.
The GR-mediated induction of H3K4me3 was dependent on
Merm1 expression (Fig. 5, E and F). However, Merm1 was also
found to mediate basal H3K79me2 (Fig. 5, E and F). After acti-
vation of GR, this methylation mark was reduced, again in a
Merm1-dependent manner. The H3K9memark was abrogated
at GL-3 in the absence of Merm1 (Fig. 5E). These results sup-
port the existence of a coordinated histone methylation
response to GR recruitment that is mediated at least in part by
Merm1.
Merm1MediatesCytokine-inducedResistance toGlucocorticoid—
Merm1 expression may be a mechanism to regulate GR func-
tion both by controlling GR access to target sites and by affect-
ing or executing GR-directed methylation of histones. To
investigate possible physiological signals regulating Merm1
expression, a panel of stimuli was screened, including cytokines
and growth factors. Of these the proinflammatory cytokines
TNF and IFN were tested in combination, as they are
together known to render target cells insensitive to GC (36)
(Fig. 6A). Incubationwith either cytokine alonewas insufficient
to affect Merm1 expression, but both together significantly
reduced Merm1 protein levels (Fig. 6B).
In an attempt to restore glucocorticoid sensitivity, Merm1
was overexpressed in the presence of TNF and IFN.
Transfection with a Merm1 expression vector greatly
increased Merm1 protein concentration, but treatment with
combined TNF/IFN still reduced Merm1 protein accu-
mulation (Fig. 6C).
This reduction inMerm1 protein fromboth endogenous and
ectopic expression suggested a post-translational mechanism
of regulation (Fig. 6C). We had earlier identified ubiquitin and
ubiquitinylation enzymes within the Merm1 interactome, and
reports had suggested potential sites for ubiquitinylation on
Merm1 (37, 38). Mutation of these two lysines (K180R/K196R)
rendered Merm1 resistant to degradation in response to the
combined proinflammatory cytokines (Fig. 6D), and moreover,
the mutated Merm1 protein was a more effective co-activator
for GR than wild-type Merm1 in the presence of TNF/IFN,
potentially by enhanced expression or stability within the com-
plex (Fig. 6E).
The discovery of a pathway linking proinflammatory cyto-
kines through loss of Merm1 protein to impaired GR function
in cells prompted us to investigate human lung tissue, a prom-
inent site of Merm1 expression. Indeed, in human fetal lung
explants combined IFN/TNF also suppressed Merm1 pro-
tein levels (Fig. 6F). As predicted, this was accompanied by loss
of GR recruitment to the consensus GRE upstream of the GILZ
gene transcription start site (Fig. 6G).
Merm1 Expression Is Suppressed in Human Lung Diseases
Associated with GC Resistance—To establish if these findings
are clinically relevant we addressed expression of Merm1 pro-
tein in human lung pathologies to test the hypothesis that
inflammatory processes would be associated with loss of
Merm1 protein. A human pathological lung tissue microarray
was analyzed for Merm1 immunoreactive intensity by three
masked observers (Fig. 7). Representative sections are shown
(Fig. 7A) with quantification given by disease type (Fig. 7, B and
C). Inflammatory (Fig. 7B) and neoplastic lung pathologies (Fig.
7C) were grouped revealing a significant loss of Merm1 protein
expression associated with both disease processes.
DISCUSSION
Recent discoveries have identified the importance of chro-
matin architecture for directing GR to its binding sites, there-
fore offering an explanation for tissue-specific actions of a ubiq-
uitously expressed transcription factor (10, 39). In addition, it
has been recognized that the actions of theGR to regulate target
gene transcription are, in part, mediated by directed chromatin
remodeling,with resulting changes in the access to, and binding
of other transcription factors (15, 40–43). Most recently it has
become clear that GR and other transcription factorsmay asso-
ciate with their binding sites in a highly dynamic state (44–46).
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Therefore, much interest has been directed at understanding
howGR access to target sites in the genome is regulated and the
mechanisms underlying subsequent GR-directed chromatin
remodeling. We have now identified a novel regulator of this
process, Merm1, that affects both GR access to target sites and
also mediates GR-regulated histone modification. As we find
that Merm1 protein is targeted for ubiquitin-mediated degra-
dation by proinflammatory cytokine signaling, these discover-
ies link inflammation with gating of GR access to the genome
and tissue sensitivity to glucocorticoid.
We initially identified Merm1 in a co-activator screen (27,
30). The co-activation effectwas found to be dependent on both
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the SAM and methyltransferase domains, although previous
studies had identified Merm1 as mediating induction of the
repressive chromatin mark H3K9me. Further evidence for a
role of Merm1 in transcriptional regulation is provided by a
recent proteomic analysis of steroid receptor transcription fac-
tor complexes in which Merm1 protein was identified (47).
Merm1 gene expression was near ubiquitous in human tis-
sues but with particularly high levels in bronchial epithelium,
prompting examination ofMerm1 in lung pathologies.We also
studied Merm1 expression in immune cell types in response to
activation, as these are prominent targets for GC therapy. We
found induction of Merm1 gene expression in both B and
CD8 T lymphocytes, again supporting a role for Merm1 in
inflammatory signaling.
As Merm1 is a candidate putative histone methyltransferase
(26), we anticipated a role in chromatin modification but ini-
tially used anunbiased proteomic approach to gain insights into
function and regulation. These studies revealed that Merm1
was a likely target for ubiquitinylation, Merm1 bound chroma-
tin component proteins, and Merm1 did not bind directly to
GR.However,Merm1did co-immunoprecipitatewithGRIP1, a
chromatin-modifying enzyme, and GR co-modulator protein
(13, 36). Merm1 also bound a number of enzymes, including
histone acetyltransferases, associated with transcriptionally
active chromatin, and the histone-binding protein RBBP7,
which interacts with histone H3 in an H3K4me3-dependent
manner (33).
Merm1 modulated GR regulation of a number of endoge-
nous target genes, both positively andnegatively. Thewell char-
acterized GR target gene GILZ was analyzed further. GILZ is a
potent anti-inflammatory mediator, and its induction by GR
plays an important role in the anti-inflammatory repertoire
activated by glucocorticoid treatment (48). GR binding to the
two well defined GREs (35) was demonstrated along with
Merm1.
Loss ofMerm1 had a dramatic effect on recruitment of GR to
the twoGREs, but there was little impact on histone acetylation
(Fig. 5C). Therefore, we examined candidate histone methyla-
tion changes. H3K4me3 is a reliable mark for active promoters,
and we revealed a striking induction at the two GILZ GREs in
response to ligand activation of the GR. In contrast, we also saw
a marked decrease in the H3K79me2 mark (Fig. 5E).
H3K79me2 is only known to be catalyzed by DOT1L and is
best-characterized as an elongation chromatinmark associated
with transcriptionally active chromatin (25, 49). Recent studies
have demonstrated at a pan-genomic level asynchronous his-
tone modifications accompanying gene transcription, and so
this may be an example of actively remodeling chromatin
driven by binding of the GR (50).
Merm1 knockdown dramatically reduced basal H3K79me2,
especially at GL-3, but had minimal effects on basal H3K4me3.
However, knockdown of Merm1 effectively abolished the GR
induction of the H3K4me3 signal. Taken together this suggests
thatMerm1 is required for themaintenance of open chromatin
at the GILZ locus to facilitate GR loading on the response ele-
ments. The increase in H3K4 trimethylation with reduction in
H3K79 dimethylation in response to GR activation by ligand
suggests coordinated histonemodificationwhereby one change
influences another. Loss ofMerm1 prevents both changes, sug-
gesting several possibilities. It may be that loss of the
H3K79me2 mark inhibited GR recruitment and thereby acqui-
sition of the H3K4me3 mark either catalyzed directly by
Merm1or the activatingMLLcomplex recruited to theGR (20).
Alternatively, the driving event may be the gain of methylation
marks on H3K4 as a result of GR activation of Merm1 and that
this mark serves to recruit histonemethyltransferases targeting
H3K79. However, it is clear that loss of Merm1 acts to regulate
GR recruitment, and the chromatinmark observedmost clearly
under basal conditions is the loss of H3K79me2. For this reason
it seemsmore likely thatMerm1 is required for maintenance of
H3K79me2.
There are many examples of collaborative and antagonistic
relationships between different histone marks. For example
CARM1 and PRMT1 act to enhance histone arginine methyla-
tion in response to estrogen receptor activation, and a further
enzyme, PADI4, also a target of estrogen receptor, reverses the
change by converting methylated arginine to citrulline (51).
Also, dimethylation ofH3R2 is prevented byH3K4me3 and vice
versa (20).
We identified in a model of acquired GC resistance (com-
bined IFN and TNF) (36) that Merm1 protein expression
was significantly reduced in a ubiquitination-dependent man-
ner both in cell lines and human lung explants. In both cases
loss of Merm1 was accompanied by loss of GR recruitment to
GREs.
Our data suggested that Merm1 may be particularly impor-
tant in the regulation of normal lung epithelial function. There-
fore, we profiled Merm1 protein expression in a human lung
tissue array and found a marked loss both in inflammatory and
neoplastic disease. As pulmonary neoplasia frequently develops
FIGURE 6.Merm1mediates cytokine-induced glucocorticoid resistance. A, A549 were treated with 10 ng/ml TNF and 500 units/ml IFN for 16 h. 100 nM
Dex was added for a further 6 h as indicated before RNA extraction. GILZ transcript abundance was measured by RT-PCR and is expressed as -fold induction
fromcontrol cells. Graphs show themean S.D. (n
3). *,p	0.05, onewayANOVA followedbyBonferroni test.B, A549 cellswere treatedwith either 10ng/ml
TNF or 500 units/ml IFN alone or both TNF and IFN in combination for 16 h. Cells were lysed and immunoblotted for Merm1 and tubulin expression. The
experiment was performed on three occasions with similar results. C, A549 cells were transfected with 1.2 g of Merm1 expression vector or empty plasmid
(cmv.SP6). After overnight incubation, cells were treatedwith 10 ng/ml TNF and 500 units/ml IFN for another 16 h. Cells were treatedwith 100 nMDex for 6 h
before harvest. Under these conditions lysates were analyzed by immunoblot for Merm1, GR, and tubulin expression. D, A549 cells were transfected with 1.2
g of WT Halo-Merm1 expression vector, K180R/K196R Merm1, or empty plasmid (pHalo). After overnight incubation, cells were treated with 10 ng/ml TNF
and 500 units/ml IFN for another 16 h and then harvested for immunoblot analysis of Halo-Merm1 protein. Experiments were repeated on three occasions
with similar results. E, A549 cells were transfected with 1.2 g of WT Halo-Merm1 expression vector, K180R/K196R Merm1, or empty plasmid (pHalo) as in D.
After overnight incubation, cellswere treatedwith 10ng/ml TNF and500units/ml IFN for another 16h. Cellswere treatedwithDex100nMas indicated. After
lysis GILZmRNAwasquantitatedbyquantitative RT-PCR.Graphs show themean S.D. (n
3). *,p	0.05using an independent Student’s t test. F, human fetal
lung explants were treated with TNF and IFN (as described above) and immunoblotted (IB) for Merm1 and -actin. Triplicate experiments are shown. G,
human fetal lung was treated as in F and GR ChIP was performed using primers for the GL-3 region of GLIZ promoter (as in Fig. 5). Data are presented as the
mean S.D. (n
 6). Statistical significance was determined using a Mann Whitney test. *, p	 0.05.
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on a tissue background of chronic inflammation, it is perhaps
no surprise to find a similar pattern of Merm1 expression in
both disease processes. Of course, the earlier discovery of
Merm1 as a regulator of distant metastases is also relevant in
the context of pulmonary neoplasia (26).
Nuclear receptors are proposed to be pioneer factors capable
of inducing open chromatin to permit binding of secondary
regulatory factors (52–54). However, more recently genome-
wide analysis suggests that themajority of GR binding occurs to
constitutively accessible sites (10, 55). Our data identifyMerm1
as a novel chromatin-modifying enzyme implicated not only in
regulating GR access to target sites but also in mediating GR
chromatin remodeling activity. We show also that Merm1 is
negatively regulated by proinflammatory cytokines, resulting in
impaired GC target gene regulation. We propose, therefore,
that inflammation re-programs chromatin, in part through
suppression of Merm1, affecting GR access to target genes and
limiting subsequent chromatin remodeling activity. The
FIGURE 7.Merm1 expression in Lung diseases. A, Merm1 expression in a human lung disease tissue array. Human lung sections from Insight Biotechnology
(LC487) were analyzed for Merm1 protein expression by immunohistochemistry; anti-Merm1 antibody (1:100). Low and high magnification views are pre-
sented for the different pathological states analyzed. The expression of Merm1 in each core sample was estimated by three masked observers scoring four
microscope fields for each core. Scale bar, 100 um). Specific antibody binding was disclosed by 3,3-diaminobenzidine (brown) and nuclei counterstained with
toluidine blue. B and C, the quantification of Merm1 expression seen in the different pathological states in (A) is presented. Expression was estimated on an
arbitrary scale from1–4,with 4 being very intense staining. Cancer pathology is presented in B, and inflammatory pathology is presented inC.NL, normal lung;
All Can, all cancer states combined;HS, hyperplasia of the stroma; SqCC, squamous cell carcinoma; AC, adenocarcinoma; SmCC, Small cell carcinoma. C, normal
lung repeated from B. All infect, all infection scores were combined; LP, lobar pneumonia; PT, pulmonary tuberculosis; PF, pulmonary fibrosis; IP, inflammatory
pseudotumor. Analysis was by one-way ANOVA with Bonferroni post hoc tests. **, p	 0.01, ***, p	 0.001 compared with normal lung.
Merm1Mediates Glucocorticoid Resistance
8944 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 13•MARCH 28, 2014
 at U
M
IST on M
ay 13, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Merm1-dependent GR cistrome is likely to be important in
understanding how best to target pulmonary inflammation.
Targeting Merm1 expression or function may be a viable strat-
egy for potentiating glucocorticoid related anti-inflammatory
action in human pulmonary inflammatory disease or may
inform the design of novel GR ligands capable of re-directing
GR in a Merm1-deficient cellular environment.
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1 
 
Supplemental Information 
Supplementary materials and methods 
ChIP primers 
GILZ1       Fwd AGT TGG TAC  AAG AAA GTG C    
Rev CTC GTA TGT  CAC AAA CTC C; GILZ2      Fwd   AAA GAG TAG AAT GTG GAG 
ACT  Rev  GCA CAG GTC  CAT GCT AAT C; GILZ3 Fwd                    GGG AAT TCT 
GAT ACC AGT TAA GC,   Rev  GGG AGA CAA TAA TGA TCT CAG GA. 
 
Steroid co-regulator primers 
SRC1 Fwd TGCCTC CGG GTA TCA GTC ACC AG, SRC1  Rev AGG CGT GGG CTG 
GTT CTG GAC AG; GRIP1 Fwd GTG GTA TGC CAG CAA CTA TGAGC,  
GRIP1 Rev TGG ATC AGG TTG CTGACT TAT TCC G; CARM1Fwd 
CACACCGACTTCAAGGACAA ,CARM1 Rev AAAAACGACAGGATCCCAGA. Β-Actin 
Fwd GTG GGG CGC CCC AGG CAC CA, Β-Actin B Rev CTC CTT AAT GTC ACG 
CAC GAT TTC. 
 
Merm1 mutagenesis 
Mutagenesis was carried out using Quik Change kit, used according to the manufacturer’s 
instructions (Agilent Technologies) using the following primers: Merm1 K180RFwd     
GATCACAACCCA GGCCACAAGGGCAGG CTTCTCCGGTGG, Merm1 K180RRev         
CCACCGGAGAA GCCTGCCCTTGTGGC CTGGGTTGTGATC, 
 Merm1 K196RFwd GACTACCCT AACAGTGCCAGAGCAAAG AAATTCTACCTC 
Merm1K196RRev GAGGTAGAAT TTCTTTGCTCTGGCA CTGTTAGGGTAGTC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Supplementary figure legends 
 
 
Figure S1. Merm1 overexpression does not enhance trans-repression. HeLa cells were 
transiently co-transfected with NRE-Luc, and as indicated with either GRIP1, Merm1, or an 
empty plasmid (pcDNA3 or cmv.SP6 vector see experimental procedures section for details), 
and treated with 0.5 or 5 ng/ml TNFα and 100 nM Dex for 16 hours before luciferase assay. 
Results are expressed as fold repression (mean and standard deviation), experiments were 
performed in triplicates, on three separate occasions  
 
Figure S2. Merm1 co-activates MR, PR and AR.  HEK293T cells were transiently co-
transfected with 0.5μg of TAT3-Luc reporter, 0.01μg Renilla reporter, 0.3 μg of Merm1 or 
cmv.SP6 empty vector (EV) and 0.5 μg of Mineralocorticoid receptor (MR), progesterone 
receptor (PR) or androgen receptor (AR) expression vectors, as indicated. Twenty four hours 
after transfection, cells were incubated with corticosterone (10nM) for MR; progesterone 
(10nM) for PR; or dihydrotesterone (DHT) (10nM) for AR, for 16hrs before luciferase assay. 
Graphs show mean and standard deviation, experiments were performed in triplicates, on 
three separate occasions. RLU, corrected relative light unit. ** p<0.01 data compared using 
independent samples Student’s t test. 
 
Figure S3. Expression of Merm1 mutants in HEK293T cells. Merm1 mutants were 
expressed in HEK293T cells (as described in the experimental procedures). Expression levels 
were determined by western blotting, using an anti-Merm1 or β-actin antibody to determine 
equal loading (molecular weight markers shown in kDa). Control Sp6 (empty plasmid), 
Merm1 wild type [WT] (32 kDa), Merm1 nuclear localisation domain mutant, ΔNL (29 kDa); 
Merm1 SAM-domain mutant, ΔSAM (14 kDa), and Merm1 methyltransferase domain 
mutant, ΔMethT (29 kDa). 
 
Figure S4. Merm1 siRNA does not affect other steroid co-regulators. A549 cells were 
transfected with 10nM (s41530) or control siRNA (Dharmacon siCONTROL Nontargeting 
siRNA) for 48 hours and prior to RNA extraction. The expression of Merm1, SRC1, GRIP1 
and CARM1 were measured by qRT-PCR, with β-actin as a house-keeping gene. Graphs 
show mean gene expression and standard deviation, experiments were performed in 
triplicates, on three separate occasions. 
 
Figure S5. Merm1 siRNA inhibits DEX-induced gene expression. A549cells were 
transfected with 10nM Merm1(s41530) or control siRNA (Dharmacon siCONTROL 
Nontargeting siRNA) for 48 hours.  Cells were then treated with dexamethasone (DEX 100 
nM) for 2 hours and then RNA extracted. The expression of the GILZ gene was measured by 
qRT-PCR, with β-actin as a house-keeping gene. Graphs show mean gene expression and 
standard deviation, experiments were performed in triplicates, on three separate occasions.  * 
p<0.05 data compared using independent samples Student’s t test. 
 
Figure S6. Merm1 siRNA inhibits DEX-induced MMTV-reporter gene activity. A549 
cells were transfected with 10nM Merm1 or control siRNA for 24 hours and then were 
transiently co-transfected with 0.5μg of MMTV-Luciferase reporter, 0.01μg Renilla reporter 
and incubated for a further 24 hours, cells were then treated with DEX (100 nM), for 16hrs 
before luciferase assay. Graphs show mean luciferase and standard deviation, experiments 
were performed in triplicates, on three separate occasions * p<0.05 data compared using 
independent samples Student’s t test. 
 
Figure S7. GILZ1 region (GL-1) serves as a non-GR binding (negative) control region 
for the ChIP assay. HeLa cells were treated with vehicle or 100nM Dex for 1hr. Following 
fixation and chromatin extraction (see Experimental procedures), ChIP assays were 
3 
 
performed using antibodies against, GR and Merm1 (with IgG as a control). GR binding 
regions were analysed with primer pairs for GL-1, 2 and 3 promoter regions. PCR products 
were resolved on agarose gels and visualized by ethidium bromide staining (representative 
images shown, 3 individual gels). 
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Fig S7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
 
Supplementary table 1 Data-Merm1 interacting proteins and network analysis.  Full list 
of interacting proteins is available (see merm1 and pHalo interacting proteins.xls)  
 
Table S1- Merm1 interacting proteins 
 
Merm1 interacting protein Peptides and 
%Coverage 
Function (taken from 
Uniprot) 
RuvB-like 1 and 2 7/41.9 and 5/28.3 A member the NuA4 histone 
acetyltransferase complex 
E3 ubiquitin-protein ligase 
HUWE1 
11/13.9 E3 ubiquitin-protein ligase that 
mediates ubiquitination and 
proteasomal degradation  
E3 ubiquitin-protein ligase 
UBR5 
15/23.0 E3 ubiquitin-protein ligase and 
regulator of DNA damage 
responses 
Nucleosome assembly protein 
1-like 1 (NAP1) 
 
5/50.24 Interacts with histones, possibly 
involved with  chromatin 
formation and cell proliferation 
HCLS1-associated protein X-1 
(HAX1) 
 
5/53.7 Promotes cell survival and cell 
migration, interacts with XIAP, 
cleaved by caspase-3 during 
apoptosis 
Nuclease-sensitive element-
binding protein 1  
3/53.7 Involved in  pre-mRNA splicing 
regulation. Binds and stabilizes 
cytoplasmic mRNA. 
Component of the CRD-
mediated complex that 
promotes MYC mRNA 
stability. 
Histone-binding protein RBBP7  
 
4/35.4 Core histone binding protein, 
targets chromatin remodeling 
factors 
Histone acetyltransferase type 
B (HAT1) 
 
4/29.4 Acetylates soluble but not 
nucleosomal histone H4. 
Possibly involved in 
nucleosome assembly during 
DNA replication and repair. 
Proteasome activator complex 
subunit 3  
 
 
2/22.8 Subunit of the 11S REG-gamma 
proteasome regulator. 
v-Raf-1 murine leukemia viral 
oncogene homolog 1 ( RAF1) 
 
1/13.5 Serine/threonine-protein kinase, 
regulation of mitogen-activated 
protein kinase cascades 
Melanoma-associated antigen 
D2 
10/36.3 Suppresses the expression of 
tumor necrosis factor-related 
apoptosis-inducing ligand 
(TRAIL) death receptor 2  
Cyclin-dependent kinase 
inhibitor 2A 
 
1/6.1 Tumour suppressor, interacts 
with UBE2I/UBC9 and 
enhances sumoylation of a 
number of its binding partners, 
also  binds to HUWE1 
12 
 
Cyclin-dependent kinase 1  
 
3/40.71 serine/threonine kinase, cell 
cycle control 
tRNA methyltransferase 112 
homolog (Trmt112) 
4/53.6 Participates both in methylation 
of protein and tRNA species. 
The heterodimer with 
HEMK2/N6AMT1 catalyzes 
N5-methylation of ETF1 on 
'Gln-185', using S-adenosyl L-
methionine as methyl donor. 
rRNA 2'-O-methyltransferase 
fibrillarin  
(FBL)  
4/50.5 Involved in pre-rRNA 
processing. Utilizes the methyl 
donor S-adenosyl-L-methionine 
to catalyze the site-specific 2'-
hydroxyl methylation of ribose 
moieties in pre-ribosomal RNA 
RNA methyltransferase-like 
protein 1 (RNMT1)  
1/11.9  
RNA-dependent helicase p72 
(DDX17) 
1/7.3 RNA-dependent ATPase 
activity. Involved in 
transcriptional regulation. 
Transcriptional coactivator for 
estrogen receptor ESR1 
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